II 

Calendar No. 658 

109TH CONGRESS 

2D SESSION S. 3983 

To amend the Public Health Service Act to provide assured compensation 

for first responders injured by experimental vaccines and drugs and 

to indemnify manufacturers and health care professionals for the administration of medical products needed for biodefense. 

IN THE SENATE OF THE UNITED STATES 

SEPTEMBER 28, 2006 

Mr. KENNEDY introduced the following bill; which was read the first time 

SEPTEMBER 30 (legislative day, SEPTEMBER 29), 2006 

Read the second time and placed on the calendar 

A BILL 

To amend the Public Health Service Act to provide assured 

compensation for first responders injured by experimental vaccines and drugs and to indemnify manufacturers and health care professionals for the administration 

of medical products needed for biodefense. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Responsible Public 

5 Readiness and Emergency Preparedness Act’’. 


ccoleman on PROD1PC71 with BILLS
2 

•S 3983 PCS

1 SEC. 2. ASSURED COMPENSATION FOR FIRST RESPONDERS 

2 INJURED BY EXPERIMENTAL VACCINES AND 

3 DRUGS. 

4 (a) REPEAL.—The Public Readiness and Emergency 

5 Preparedness Act (division C of the Department of De6 fense, Emergency Supplemental Appropriations to Ad7 dress Hurricanes in the Gulf of Mexico, and Pandemic In8 fluenza Act, 2006 (Public Law 109–148)) is repealed. 

9 (b) NATIONAL BIODEFENSE INJURY COMPENSATION

10 PROGRAM.— 

11 (1) ESTABLISHMENT.—Section 224 of the Pub12 lic Health Service Act (42 U.S.C. 233) is amended 

13 by adding at the end the following: 

14 ‘‘(q) BIODEFENSE INJURY COMPENSATION PRO15 GRAM.— 

16 ‘‘(1) ESTABLISHMENT.—There is established 

17 the Biodefense Injury Compensation Program (re18 ferred to in this subsection as the ‘Compensation 

19 Program’) under which compensation may be paid 

20 for death or any injury, illness, disability, or condi21 tion that is likely (based on best available evidence) 

22 to have been caused by the administration of a cov23 ered countermeasure to an individual pursuant to a 

24 declaration under subsection (p)(2). 

25 ‘‘(2) ADMINISTRATION AND INTERPRETA26 TION.—The statutory provisions governing the ComVerDate Aug 31 2005 03:48 Oct 01, 2006 Jkt 049200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\S3983.PCS S3983

ccoleman on PROD1PC71 with BILLS
3 

•S 3983 PCS

1 pensation Program shall be administered and inter2 preted in consideration of the program goals de3 scribed in paragraph (4)(B)(iii). 

4 ‘‘(3) PROCEDURES AND STANDARDS.—The Sec5 retary shall by regulation establish procedures and 

6 standards applicable to the Compensation Program 

7 that follow the procedures and standards applicable 

8 under the National Vaccine Injury Compensation 

9 Program established under section 2110, except that 

10 the regulations promulgated under this paragraph 

11 shall permit a person claiming injury or death re12 lated to the administration of any covered counter13 measure to file either— 

14 ‘‘(A) a civil action for relief under sub15 section (p); or 

16 ‘‘(B) a petition for compensation under 

17 this subsection. 

18 ‘‘(4) INJURY TABLE.— 

19 ‘‘(A) INCLUSION.—For purposes of receiv20 ing compensation under the Compensation Pro21 gram with respect to a countermeasure that is 

22 the subject of a declaration under subsection 

23 (p)(2), the Vaccine Injury Table under section 

24 2114 shall be deemed to include death and the 

25 injuries, disabilities, illnesses, and conditions 


ccoleman on PROD1PC71 with BILLS
4 

•S 3983 PCS

1 specified by the Secretary under subparagraph 

2 (B)(ii). 

3 ‘‘(B) INJURIES, DISABILITIES, ILLNESSES, 

4 AND CONDITIONS.— 

5 ‘‘(i) INSTITUTE OF MEDICINE.—Not 

6 later than 30 days after making a declara7 tion described in subsection (p)(2), the 

8 Secretary shall enter into a contract with 

9 the Institute of Medicine, under which the 

10 Institute shall, within 180 days of the date 

11 on which the contract is entered into, and 

12 periodically thereafter as new information, 

13 including information derived from the 

14 monitoring of those who were administered 

15 the countermeasure, becomes available, 

16 provide its expert recommendations on the 

17 injuries, disabilities, illnesses, and condi18 tions whose occurrence in one or more in19 dividuals are likely (based on best available 

20 evidence) to have been caused by the ad21 ministration of a countermeasure that is 

22 the subject of the declaration. 

23 ‘‘(ii) SPECIFICATION BY SEC24 RETARY.—Not later than 30 days after the 

25 receipt of the expert recommendations deVerDate Aug 31 2005 03:48 Oct 01, 2006 Jkt 049200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\S3983.PCS S3983

ccoleman on PROD1PC71 with BILLS
5 

•S 3983 PCS

1 scribed in clause (i), the Secretary shall, 

2 based on such recommendations, specify 

3 those injuries, disabilities, illnesses, and 

4 conditions deemed to be included in the 

5 Vaccine Injury Table under section 2114 

6 for the purposes described in subparagraph 

7 (A). 

8 ‘‘(iii) PROGRAM GOALS.—The Insti9 tute of Medicine, under the contract under 

10 clause (i), shall make such recommenda11 tions, the Secretary shall specify, under 

12 clause (ii), such injuries, disabilities, ill13 nesses, and conditions, and claims under 

14 the Compensation Program under this sub15 section shall be processed and decided tak16 ing into account the following goals of such 

17 program: 

18 ‘‘(I) To encourage persons to de19 velop, manufacture, and distribute 

20 countermeasures, and to administer 

21 covered countermeasures to individ22 uals, by limiting such persons’ liability 

23 for damages related to death and such 

24 injuries, disabilities, illnesses, and 

25 conditions. 


ccoleman on PROD1PC71 with BILLS
6 

•S 3983 PCS

1 ‘‘(II) To encourage individuals to 

2 consent to the administration of a 

3 covered countermeasure by providing 

4 adequate and just compensation for 

5 damages related to death and such in6 juries, disabilities, illnesses, or condi7 tions. 

8 ‘‘(III) To provide individuals 

9 seeking compensation for damages re10 lated to the administration of a coun11 termeasure with a non-adversarial ad12 ministrative process for obtaining ade13 quate and just compensation. 

14 ‘‘(iv) USE OF BEST AVAILABLE EVI15 DENCE.—The Institute of Medicine, under 

16 the contract under clause (i), shall make 

17 such recommendations, the Secretary shall 

18 specify, under clause (ii), such injuries, 

19 disabilities, illnesses, and conditions, and 

20 claims under the Compensation Program 

21 under this subsection shall be processed 

22 and decided using the best available evi23 dence, including information from adverse 

24 event reporting or other monitoring of 

25 those individuals who were administered 


ccoleman on PROD1PC71 with BILLS
7 

•S 3983 PCS

1 the countermeasure, whether evidence from 

2 clinical trials or other scientific studies in 

3 humans is available. 

4 ‘‘(v) APPLICATION OF SECTION

5 2115.—With respect to section 2115(a)(2) 

6 as applied for purposes of this subsection, 

7 an award for the estate of the deceased 

8 shall be— 

9 ‘‘(I) if the deceased was under 

10 the age of 18, an amount equal to the 

11 amount that may be paid to a sur12 vivor or survivors as death benefits 

13 under the Public Safety Officers’ Ben14 efits Program under subpart 1 of part 

15 L of title I of the Omnibus Crime 

16 Control and Safe Streets Act of 1968 

17 (42 U.S.C. 3796 et seq.); or 

18 ‘‘(II) if the deceased was 18 

19 years of age or older, the greater of— 

20 ‘‘(aa) the amount described 

21 in subclause (I); or 

22 ‘‘(bb) the projected loss of 

23 employment income, except that 

24 the amount under this item may 

25 not exceed an amount equal to 


ccoleman on PROD1PC71 with BILLS
8 

•S 3983 PCS

1 400 percent of the amount that 

2 applies under item (aa). 

3 ‘‘(vi) APPLICATION OF SECTION

4 2116.—Section 2116(b) shall apply to in5 juries, disabilities, illnesses, and conditions 

6 initially specified or revised by the Sec7 retary under clause (ii), except that the ex8 ceptions contained in paragraphs (1) and 

9 (2) of such section shall not apply. 

10 ‘‘(C) RULE OF CONSTRUCTION.—Section 

11 13632 (a)(3) of Public Law 103–66 (107 Stat. 

12 646) (making revisions by Secretary to the Vac13 cine Injury Table effective on the effective date 

14 of a corresponding tax) shall not be construed 

15 to apply to any revision to the Vaccine Injury 

16 Table made under regulations under this para17 graph. 

18 ‘‘(5) APPLICATION.—The Compensation Pro19 gram applies to any death or injury, illness, dis20 ability, or condition that is likely (based on best 

21 available evidence) to have been caused by the ad22 ministration of a covered countermeasure to an indi23 vidual pursuant to a declaration under subsection 

24 (p)(2). 

25 ‘‘(6) SPECIAL MASTERS.— 


ccoleman on PROD1PC71 with BILLS
9 

•S 3983 PCS

1 ‘‘(A) HIRING.—In accordance with section 

2 2112, the judges of the United States Claims 

3 Court shall appoint a sufficient number of spe4 cial masters to address claims for compensation 

5 under this subsection. 

6 ‘‘(B) BUDGET AUTHORITY.—There are ap7 propriated to carry out this subsection such 

8 sums as may be necessary for fiscal year 2006 

9 and each fiscal year thereafter. This subpara10 graph constitutes budget authority in advance 

11 of appropriations and represents the obligation 

12 of the Federal Government. 

13 ‘‘(7) COVERED COUNTERMEASURE.—For pur14 poses of this subsection, the term ‘covered counter15 measure’ has the meaning given to such term in sub16 section (p)(7)(A). 

17 ‘‘(8) FUNDING.—Compensation made under the 

18 Compensation Program shall be made from the same 

19 source of funds as payments made under subsection 

20 (p).’’. 

21 (2) EFFECTIVE DATE.—This subsection shall 

22 take effect as of November 25, 2002 (the date of en23 actment of the Homeland Security Act of 2002 

24 (Public Law 107–296; 116 Stat. 2135)). 


ccoleman on PROD1PC71 with BILLS
10 

•S 3983 PCS

1 SEC. 3. INDEMNIFICATION FOR MANUFACTURERS AND 

2 HEALTH CARE PROFESSIONALS WHO ADMIN3 ISTER MEDICAL PRODUCTS NEEDED FOR 

4 BIODEFENSE. 

5 Section 224(p) of the Public Health Service Act (42 

6 U.S.C. 233(p)) is amended— 

7 (1) in the subsection heading by striking 

8 ‘‘SMALLPOX’’; 

9 (2) in paragraph (1), by striking ‘‘against 

10 smallpox’’; 

11 (3) in paragraph (2)— 

12 (A) in the paragraph heading, by striking 

13 ‘‘AGAINST SMALLPOX’’; and 

14 (B) in subparagraph (B), by striking 

15 clause (ii); 

16 (4) by striking paragraph (3) and inserting the 

17 following: 

18 ‘‘(3) EXCLUSIVITY; OFFSET.— 

19 ‘‘(A) EXCLUSIVITY.—With respect to an 

20 individual to which this subsection applies, such 

21 individual may bring a claim for relief under— 

22 ‘‘(i) this subsection; 

23 ‘‘(ii) subsection (q); or 

24 ‘‘(iii) part C. 

25 ‘‘(B) ELECTION OF ALTERNATIVES.—An 

26 individual may only pursue one remedy under 


ccoleman on PROD1PC71 with BILLS
11 

•S 3983 PCS

1 subparagraph (A) at any one time based on the 

2 same incident or series of incidents. An indi3 vidual who elects to pursue the remedy under 

4 subsection (q) or part C may decline any com5 pensation awarded with respect to such remedy 

6 and subsequently pursue the remedy provided 

7 for under this subsection. An individual who 

8 elects to pursue the remedy provided for under 

9 this subsection may not subsequently pursue 

10 the remedy provided for under subsection (q) or 

11 part C. 

12 ‘‘(C) STATUTE OF LIMITATIONS.—For pur13 poses of determining how much time has lapsed 

14 when applying statute of limitations require15 ments relating to remedies under subparagraph 

16 (A), any limitation of time for commencing an 

17 action, or filing an application, petition, or 

18 claim for such remedies, shall be deemed to 

19 have been suspended for the periods during 

20 which an individual pursues a remedy under 

21 such subparagraph. 

22 ‘‘(D) OFFSET.—The value of all compensa23 tion and benefits provided under subsection (q) 

24 or part C of this title for an incident or series 

25 of incidents shall be offset against the amount 


ccoleman on PROD1PC71 with BILLS
12 

•S 3983 PCS

1 of an award, compromise, or settlement of 

2 money damages in a claim or suit under this 

3 subsection based on the same incident or series 

4 of incidents.’’; 

5 (5) in paragraph (6)— 

6 (A) in subparagraph (A), by inserting ‘‘or 

7 under subsection (q) or part C’’ after ‘‘under 

8 this subsection’’; and 

9 (B) by redesignating subparagraph (B) as 

10 subparagraph (C); 

11 (C) by inserting after subparagraph (A), 

12 the following: 

13 ‘‘(B) GROSSLY NEGLIGENT, RECKLESS, OR

14 ILLEGAL CONDUCT AND WILLFUL MIS15 CONDUCT.—For purposes of subparagraph (A), 

16 grossly negligent, reckless, or illegal conduct or 

17 willful misconduct shall include the administra18 tion by a qualified person of a covered counter19 measure to an individual who was not within a 

20 category of individuals covered by a declaration 

21 under subsection (p)(2) with respect to such 

22 countermeasure where the qualified person fails 

23 to have had reasonable grounds to believe such 

24 individual was within such a category.’’; and 

25 (D) by adding at the end the following: 


ccoleman on PROD1PC71 with BILLS
13 

•S 3983 PCS

1 ‘‘(D) LIABILITY OF THE UNITED

2 STATES.—The United States shall be liable 

3 under this subsection with respect to a claim 

4 arising out of the manufacture, distribution, or 

5 administration of a covered countermeasure re6 gardless of whether— 

7 ‘‘(i) the cause of action seeking com8 pensation is alleged as negligence, strict li9 ability, breach of warranty, failure to warn, 

10 or other action; or 

11 ‘‘(ii) the covered countermeasure is 

12 designated as a qualified anti-terrorism 

13 technology under the SAFETY Act (6 

14 U.S.C. 441 et seq.). 

15 ‘‘(E) GOVERNING LAW.—Notwithstanding 

16 the provisions of section 1346(b)(1) and chap17 ter 171 of title 28, United States Code, as they 

18 relate to governing law, the liability of the 

19 United States as provided in this subsection 

20 shall be in accordance with the law of the place 

21 of injury. 

22 ‘‘(F) MILITARY PERSONNEL AND UNITED

23 STATES CITIZENS OVERSEAS.— 

24 ‘‘(i) MILITARY PERSONNEL.—The li25 ability of the United States as provided in 


ccoleman on PROD1PC71 with BILLS
14 

•S 3983 PCS

1 this subsection shall extend to claims 

2 brought by United States military per3 sonnel. 

4 ‘‘(ii) CLAIMS ARISING IN A FOREIGN

5 COUNTRY.—Notwithstanding the provisions 

6 of section 2680(k) of title 28, United 

7 States Code, the liability of the United 

8 States as provided for in the subsection 

9 shall extend to claims based on injuries 

10 arising in a foreign country where the in11 jured party is a member of the United 

12 States military, is the spouse or child of a 

13 member of the United States military, or is 

14 a United States citizen. 

15 ‘‘(iii) GOVERNING LAW.—With regard 

16 to all claims brought under clause (ii), and 

17 notwithstanding the provisions of section 

18 1346(b)(1) and chapter 171 of title 28, 

19 United States Code, and of subparagraph 

20 (C), as they relate to governing law, the li21 ability of the United States as provided in 

22 this subsection shall be in accordance with 

23 the law of the claimant’s domicile in the 

24 United States or most recent domicile with 

25 the United States.’’; and 


ccoleman on PROD1PC71 with BILLS
15 

•S 3983 PCS

1 (6) in paragraph (7)— 

2 (A) by striking subparagraph (A) and in3 serting the following: 

4 ‘‘(A) COVERED COUNTERMEASURE.—The 

5 term ‘covered countermeasure’, means— 

6 ‘‘(i) a substance that is— 

7 ‘‘(I)(aa) used to prevent or treat 

8 smallpox (including the vaccinia or 

9 another vaccine); or 

10 ‘‘(bb) vaccinia immune globulin 

11 used to control or treat the adverse 

12 effects of vaccinia inoculation; and 

13 ‘‘(II) specified in a declaration 

14 under paragraph (2); or 

15 ‘‘(ii) a drug (as such term is defined 

16 in section 201(g)(1) of the Federal Food, 

17 Drug, and Cosmetic Act), biological prod18 uct (as such term is defined in section 

19 351(i) of this Act), or device (as such term 

20 is defined in section 201(h) of the Federal 

21 Food, Drug, and Cosmetic Act) that— 

22 ‘‘(I) the Secretary determines to 

23 be a priority (consistent with sections 

24 302(2) and 304(a) of the Homeland 

25 Security Act of 2002) to treat, idenVerDate Aug 31 2005 03:48 Oct 01, 2006 Jkt 049200 PO 00000 Frm 00015 Fmt 6652 Sfmt 6201 E:\BILLS\S3983.PCS S3983

ccoleman on PROD1PC71 with BILLS
16 

•S 3983 PCS

1 tify, or prevent harm from any bio2 logical, chemical, radiological, or nu3 clear agent identified as a material 

4 threat under section 319F– 

5 2(c)(2)(A)(ii), or to treat, identify, or 

6 prevent harm from a condition that 

7 may result in adverse health con8 sequences or death and may be caused 

9 by administering a drug, biological 

10 product, or device against such an 

11 agent; 

12 ‘‘(II) is— 

13 ‘‘(aa) authorized for emer14 gency use under section 564 of 

15 the Federal Food, Drug, and 

16 Cosmetic Act, so long as the 

17 manufacturer of such drug, bio18 logical product, or device has— 

19 ‘‘(AA) made all reasonable 

20 efforts to obtain applicable ap21 proval, clearance, or licensure; 

22 and 

23 ‘‘(BB) cooperated fully with 

24 the requirements of the Secretary 

25 under such section 564; or 


ccoleman on PROD1PC71 with BILLS
17 

•S 3983 PCS

1 ‘‘(bb) approved or licensed 

2 solely pursuant to the regulations 

3 under subpart I of part 314 or 

4 under subpart H of part 601 of 

5 title 21, Code of Federal Regula6 tions (as in effect on the date of 

7 enactment of the National Bio8 defense Act of 2005); and 

9 ‘‘(III) is specified in a declaration 

10 under paragraph (2).’’; and 

11 (B) in subparagraph (B)— 

12 (i) by striking clause (ii), and insert13 ing the following: 

14 ‘‘(ii) a health care entity, a State, or 

15 a political subdivision of a State under 

16 whose auspices such countermeasure was 

17 administered;’’and 

18 (ii) in clause (viii), by inserting before 

19 the period ‘‘if such individual performs a 

20 function for which a person described in 

21 clause (i), (ii), or (iv) is a covered person’’. 


ccoleman on PROD1PC71 with BILLS
Calendar No. 658 

109TH CONGRESS 

2D SESSION S. 3983 

A BILL 

To amend the Public Health Service Act to provide 

ucts needed for biodefense. sionals for the administration of medical proddemnify manufacturers and health care profesby experimental vaccines and drugs and to inassured compensation for first responders injured 

SEPTEMBER 30 (legislative day, SEPTEMBER 29), 2006 

Read the second time and placed on the calendar 


ccoleman on PROD1PC71 with BILLS